A-779 TFA 是一种选择性血管紧张素-(1-7) (Ang-(1-7)) 拮抗剂,可阻断 Arachidonic acid 释放、缓激肽增强效应和降压作用,在未孕大鼠中发挥利尿作用,在妊娠晚期大鼠中发挥抗利尿作用,还可抑制妊娠晚期大鼠的饲料摄入和饮水量,并减弱与血管紧张素-(1-7) 相关的前列环素、一氧化氮和血栓素 A2 的调控作用,可用于高血压的相关研究。
A-779 TFA
产品编号: MS-S61122 分子式: C41H61F3N12O13 分子量: 986.99
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

A-779 TFA 是一种选择性血管紧张素-(1-7) (Ang-(1-7)) 拮抗剂,可阻断 Arachidonic acid 释放、缓激肽增强效应和降压作用,在未孕大鼠中发挥利尿作用,在妊娠晚期大鼠中发挥抗利尿作用,还可抑制妊娠晚期大鼠的饲料摄入和饮水量,并减弱与血管紧张素-(1-7) 相关的前列环素、一氧化氮和血栓素 A2 的调控作用,可用于高血压的相关研究。

生物实验数据

生物活性 A-779 TFA is a selective angiotensin-(1-7) (Ang-(1-7)) antagonist that blocks Arachidonic acid release, bradykinin-potentiating effects, and hypotensive effects, exerts diuretic effects in nonpregnant rats and antidiuretic effects in late-pregnant rats, inhibits food intake and water intake in late-pregnant rats, attenuates angiotensin-(1-7)-related regulation of prostacyclin, nitric oxide, and thromboxane A2, and can be used for research related to hypertension.
体外研究
(In Vitro)

A-779 (10-10 to 10-6 M) 可强效与 125I-Ang-(1-7) TFA 竞争结合转染 Mas 的 CHO 细胞,其 IC50 为 0.3 nM。
A-779 (10-8 M; 10 min pre-incubation prior to 15 min Ang-(1-7) incubation at 37°C) TFA 可阻断 Ang-(1-7) (MS-T64620) 在 Mas 转染 CHO、COS 细胞中诱导的 [3H]-Arachidonic acid 释放。

体内研究
(In Vivo)

A-779 (24 μg/kg/h;静脉注射;持续输注;8 天) TFA 可使未交配雌性 Sprague Dawley 大鼠的尿量显著增加 126%。
A-779 (24 μg/kg/h;静脉注射;持续输注;孕前 8 天至妊娠第 19 天) TFA 可使妊娠晚期的 Sprague Dawley 大鼠饲料消耗量显著降低 83%、尿量减少 76%,使妊娠中期饮水量降低 83%、妊娠晚期饮水量降低 80%,且对胎仔结局无影响。
A-779 (80 ng/min 速率静脉持续输注) TFA 可显著减弱 Captopril (MS-Q24704) 对清醒雄性 Wistar 大鼠体内缓激肽降压作用的增强效应。
A-779 (48 µg/kg;静脉注射;单次给药;100 pM;与分离的主动脉环共同孵育) TFA 可部分阻断高盐诱导的高血压雄性 Dahl 盐敏感性大鼠中 Ang-(1-7) 引发的降压反应,并能抑制 Ang-(1-7) 介导的血管舒张/血管收缩类前列腺素、一氧化氮及 cGMP 水平的所有相关变化。

Animal Model: Sprague Dawley (female, 9 weeks old)
Dosage: 24 μg/kg/h
Administration: i.v.; continuous infusion; 8 days
Result: Increased urine volume by 126%.
Tended to decrease urinary osmolality.
Did not alter chow consumption and water intake relative to vehicle controls.
Animal Model: Sprague Dawley (female, originally 9 weeks old virgin, pregnant)
Dosage: 24 μg/kg/h
Administration: i.v.; continuous infusion; 8 days pre-pregnancy through gestational day 19
Result: Decreased water consumption by 83% relative to vehicle controls in mid-pregnancy (gestational day 15).
Decreased chow consumption by 83%, decreased water consumption by 80%, and reduced urine volume by 76% relative to vehicle controls in late pregnancy (gestational day 19).
Tended to increase urinary osmolality in late pregnancy.
Had no significant effect on fluid/food intake-output balance, urinary sodium or potassium concentrations, maternal body weight, or fetal characteristics (body weight, length, number).
Animal Model: Wistar (male, 230-320 g)
Dosage: 80 ng/min
Administration: i.v.; continuous infusion
Result: Produced a significant shift of the intravenous bradykinin dose-response curve, requiring approximately two-fold higher bradykinin doses to achieve the same hypotensive effect observed with captopril alone.
Significantly attenuated the captopril-induced potentiation of intra-arterial bradykinin's hypotensive effect.
Did not significantly alter bradykinin's hypotensive effect or baseline MAP when infused alone (without captopril).
Did not modify the pressor effect of angiotensin II.
Did not change captopril's inhibitory effect on angiotensin I's pressor response.
Did not alter the captopril-induced decrease in baseline MAP.
Animal Model: Dahl salt-sensitive (male, 4-5 weeks of age, high 8.0% NaCl salt diet for 2 weeks or low 0.3% NaCl salt diet)
Dosage: 48 µg/kg (in vivo); 100 pmol (ex vivo tissue incubation)
Administration: i.v.; single dose (in vivo); incubated with isolated aortic rings (ex vivo)
Result: Blocked the maximal MAP reduction of -14 mm Hg induced by Ang-(1-7) in high salt diet rats, resulting in a significantly attenuated blood pressure decrease.
Prevented the Ang-(1-7)-induced increase in plasma 6-keto-PGF1α levels, maintaining levels near basal values.
Prevented the Ang-(1-7)-induced decrease in plasma TXB2 levels, maintaining levels near basal values.
Prevented the Ang-(1-7)-induced increase in plasma nitric oxide levels, maintaining levels near basal values.
Prevented the Ang-(1-7)-induced increase in aortic ring 6-keto-PGF1α levels (from 31 to 49 pg/mL/mg ring wt, maintained at 36 pg/mL/mg ring wt) and PGE2 levels (from basal 22 to Ang-(1-7)-induced 33 pg/mL/mg ring wt, maintained at 21 pg/mL/mg ring wt) in high salt diet rats.
Attenuated the Ang-(1-7)-induced decrease in aortic ring TXB2 levels (from basal 44 to Ang-(1-7)-induced 23 pg/mL/mg ring wt, increased to 37 pg/mL/mg ring wt) in high salt diet rats.
Prevented the Ang-(1-7)-induced increase in nitric oxide levels in aortic rings from both high and low salt diet rats.
Totally abolished the Ang-(1-7)-induced 52% increase in aortic ring cGMP levels (from basal 102 to Ang-(1-7)-induced 212 fmol/mg protein, maintained at 67 fmol/mg protein) in high salt diet rats.
Had no significant effect on MAP, plasma 6-keto-PGF1α, TXB2, nitric oxide, aortic ring 6-keto-PGF1α, PGE2, TXB2, nitric oxide, or cGMP levels compared to basal values in either diet group.

化学信息

分子量 986.99
分子式 C41H61F3N12O13

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础